VintaBio
VintaBio is a Philadelphia-based CDMO providing viral vector (AAV and lentiviral) manufacturing services to cell and gene therapy developers, using its proprietary VintaProcess™ Intensified Adherent Technology platform from a 22,434 sq ft cGMP facility.
- Company typePrivate
- Founded2023
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What VintaBio does
VintaBio is a Philadelphia-based contract development and manufacturing organization (CDMO) founded in 2020 that provides viral vector manufacturing services for cell and gene therapy developers. The company emerged from stealth in April 2023 with $64 million in funding led by Decheng Capital and operates a 22,434 sq ft purpose-built facility at the Philadelphia Navy Yard featuring BSL2-ISO7/ISO8 classified cleanrooms and 5 dedicated cGMP suites for cell expansion, solution prep, processing, and fill/finish, plus dedicated process development, toxicology (GLP), and RUO vector core areas.
The company's core offering is VintaProcess™, a proprietary Intensified Adherent Technology platform that keeps HEK293 cells in their natural adherent state within small-footprint bioreactors, contrasting with conventional suspension-based viral vector production. The platform comprises six integrated components — VintaCell (cGMP cell line), VintaSeed (surface area amplification), VintaFect (transfection reagent), VintaSep (purification system), and VintaDP (final formulations) — and is claimed to deliver 43% lower process time, 30% lower raw material costs, 5x higher high-purity vector output, and 90% full capsids. Services span process development (platform bridging, scale-up, process characterization, QbD/CMC support), cGMP manufacturing (AAV and LVV production, fill/finish), and analytical development for clinical and commercial programs.
VintaBio operates a fee-for-service CDMO business model targeting biotech and pharmaceutical companies developing cell and gene therapies, with a horizontal go-to-market focused exclusively on viral vector manufacturing for the CGT developer segment. The company sells through direct B2B enterprise engagement with biotech and pharma leadership, leveraging the team's pedigree — including co-developers of FDA-approved Luxturna and Zolgensma from Spark Therapeutics — to win contracts. Pricing is quote-based and not publicly disclosed, with revenue generated through project-based contracts. Customer logos are not disclosed in available sources.
VintaBio firmographics
Firmographics- Name
- VintaBio
- Legal name
- VintaBio LLC
- Website
- https://vintabio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VintaBio is a Philadelphia-based CDMO providing viral vector (AAV and lentiviral) manufacturing services to cell and gene therapy developers, using its proprietary VintaProcess™ Intensified Adherent Technology platform from a 22,434 sq ft cGMP facility.
- Ownership category
- akta.pro rank
VintaBio industry classification
Industry- Product category
- Biopharmaceutical CDMO — Viral Vector Manufacturing Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where VintaBio is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
VintaBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Manufacturing Services: VintaBio operates as a contract development and manufacturing organization (CDMO), providing fee-for-service viral vector manufacturing to biotech and pharmaceutical clients. Services span from process development through cGMP manufacturing and analytical testing, with revenue generated through project-based contracts for clinical and commercial supply.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
VintaBio product offering
Product offeringCore offering
VintaBio is a contract development and manufacturing organization (CDMO) that produces viral vectors—primarily AAV and lentiviral vectors—for biotech and pharmaceutical companies developing cell and gene therapies. The company delivers end-to-end manufacturing services spanning process development, cGMP manufacturing, and analytical testing using its proprietary VintaProcess™ Intensified Adherent Technology platform, operated from a 22,434 sq ft BSL2-ISO7/ISO8 manufacturing facility in Philadelphia, Pennsylvania.
Product overview
VintaBio is a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies. The company's core offering is the proprietary VintaProcess™ platform, which includes five integrated components (VintaCell, VintaSeed, VintaFect, VintaSep, and VintaDP) that work together to enable high-yield, high-purity viral vector production. This platform is supported by end-to-end services including Process Development, cGMP Manufacturing, and Analytical Development, all delivered from the company's state-of-the-art 22,434 sq ft facility in Philadelphia featuring BSL2 containment and ISO7/ISO8 classified cleanrooms with 5 dedicated cGMP suites.
Differentiator
Problem solved
Functional benefit
Brands
- VintaProcess™: Advanced Intensified Adherent Technology platform that generates high-yield, high-purity viral vectors for clinical and commercial cell and gene therapies using a small footprint single-stream process.
- VintaCell
- VintaSeed
- VintaFect
- VintaSep
- VintaDP
Products and services
- Process Development Services End-to-end solution for viral vector manufacturing spanning cell line through drug product, with platform bridging, pre-clinical and toxicology batches, scale up/out, process characterization, Quality by Design (QbD) and CMC support, analytical development, and formulation development for cell and gene therapy developers.
- cGMP Manufacturing Services cGMP viral vector manufacturing for cell and gene therapy programs, including cGMP cell line development, AAV and lentiviral vector (LVV) production, process validation, CMC support, cGMP analytical testing, stability strategy support, assay qualification and validation, and formulation/fill-finish operations.
- Analytical Development Services Analytical services for viral vector product release including assay development, assay qualification and validation, in-process sample testing, lot release testing, and stability support for cell and gene therapy developers.
Quantifiable outcome
- 43% reduction in process time
- +5 more outcomes
Companies that use VintaBio
Customer profileSegments1 record
Ideal customer profiles1 record
VintaBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
VintaBio partnerships and signals
Strategic signalScale indicators7 records
Recent moves8 records
Expansion highlights5 records
VintaBio competitors and assessment
Company assessmentBroad incumbents
- Catalent (Paragon Gene Therapy): Large, established CDMO with a dedicated gene therapy viral vector business (formerly Paragon BioServices). Directly comparable as a viral vector CDMO serving AAV/lentiviral programs for cell and gene therapy developers, but at much larger scale and with broader service portfolio.
- Lonza Cell & Gene: Global biopharma CDMO with significant viral vector and cell therapy manufacturing capacity. Comparable as a viral vector CDMO for gene therapy developers, but operates globally with much larger installed capacity and broader modality coverage.
- AGC Biologics: Global CDMO with cell and gene therapy viral vector capabilities alongside biologics services. Comparable as a viral vector CDMO, but with broader portfolio including mammalian and microbial biologics manufacturing.
- Thermo Fisher Scientific Viral Vector Services: Global life sciences company with viral vector manufacturing services for cell and gene therapy. Comparable as a viral vector CDMO, but operating as part of a much larger life sciences portfolio including tools, services, and pharma services.
Direct peers
- Center for Breakthrough Medicines: King of Prussia, PA-based CGT CDMO offering viral vector, cell therapy, and plasmid manufacturing. Directly comparable as a viral vector CDMO for AAV/lentiviral programs; VintaBio's VP Technology Lucia Fernandez previously headed viral vector tech transfer there.
- National Resilience: U.S.-focused biotech manufacturer with end-to-end capabilities across biologics, viral vectors, and cell therapies. Directly comparable as a viral vector CDMO for gene therapy developers, with broader modality coverage but similar domestic, end-to-end positioning.
- Andelyn Biosciences: Columbus, Ohio-based CDMO specializing in AAV and other viral vectors for gene therapy, spun out of Nationwide Children's Hospital. Directly comparable as a viral vector CDMO with cGMP manufacturing, process development, and analytical services for clinical and commercial gene therapy programs.
- Forge Biologics: Columbus, Ohio-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Directly comparable as a viral vector CDMO with end-to-end process development, cGMP manufacturing, and fill/finish for AAV-based gene therapy programs.
- Genezen: Indianapolis-based viral vector CDMO specializing in AAV and lentiviral manufacturing for gene therapy developers. Directly comparable as a viral vector CDMO offering process development, cGMP manufacturing, and analytical services to early-stage and clinical-stage gene therapy clients.
Regional players
- Skyepharma (Vectalys / PeptiMimesis): European-based CDMO with viral vector manufacturing expertise for gene therapy applications. Comparable as a viral vector CDMO with similar modality focus, but operates primarily in EU geography rather than U.S.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VintaBio social profiles
Digital presenceVintaBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
VintaBio leadership team
Management profileNumber of profiles
Profiles5 records
VintaBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VintaBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VintaBio
What does VintaBio do?
VintaBio is a contract development and manufacturing organization (CDMO) that produces viral vectors—primarily AAV and lentiviral vectors—for biotech and pharmaceutical companies developing cell and gene therapies. The company delivers end-to-end manufacturing services spanning process development, cGMP manufacturing, and analytical testing using its proprietary VintaProcess™ Intensified Adherent Technology platform, operated from a 22,434 sq ft BSL2-ISO7/ISO8 manufacturing facility in Philadelphia, Pennsylvania.
Is VintaBio a public or private company?
VintaBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was VintaBio founded?
VintaBio was founded in 2023. It employs 11 to 50 people.
Where is VintaBio based?
VintaBio is headquartered in Philadelphia, United States, in the North America region.
How does VintaBio make money?
One revenue line is on record: contract Manufacturing Services.
Who are VintaBio's main competitors?
Broad incumbents on record are Catalent (Paragon Gene Therapy), Lonza Cell & Gene, AGC Biologics and Thermo Fisher Scientific Viral Vector Services. Direct peers are Center for Breakthrough Medicines, National Resilience, Andelyn Biosciences, Forge Biologics and Genezen. Skyepharma (Vectalys / PeptiMimesis) is listed as a regional player.
Does VintaBio have an API?
No public API is recorded for VintaBio.
What industry is VintaBio in?
VintaBio's product category is Biopharmaceutical CDMO — Viral Vector Manufacturing Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2834.